KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Moderna (MRNA) over the last 8 years, with Q3 2025 value amounting to $199.0 million.

  • Moderna's Change in Accured Expenses rose 30612.24% to $199.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$166.0 million, marking a year-over-year increase of 7970.66%. This contributed to the annual value of -$385.0 million for FY2024, which is 1323.53% down from last year.
  • Moderna's Change in Accured Expenses amounted to $199.0 million in Q3 2025, which was up 30612.24% from -$14.0 million recorded in Q2 2025.
  • Over the past 5 years, Moderna's Change in Accured Expenses peaked at $696.0 million during Q3 2023, and registered a low of -$1.1 billion during Q4 2022.
  • Its 5-year average for Change in Accured Expenses is -$35.4 million, with a median of $49.0 million in 2022.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 247500.0% in 2021, then crashed by 53421.05% in 2023.
  • Moderna's Change in Accured Expenses (Quarter) stood at $389.0 million in 2021, then tumbled by 381.23% to -$1.1 billion in 2022, then soared by 63.16% to -$403.0 million in 2023, then skyrocketed by 107.44% to $30.0 million in 2024, then soared by 563.33% to $199.0 million in 2025.
  • Its Change in Accured Expenses stands at $199.0 million for Q3 2025, versus -$14.0 million for Q2 2025 and -$381.0 million for Q1 2025.